1. karinkaz
2. rjsllewellyn
3. fpratt
1.fpratt 06/01/2018
Orphan Drug Designation from the European Commission for bardoxolone methyl
2.karinkaz 03/01/2018
Reports top-line data from dose-escalation cohorts in motor study of omaveloxolone in patients with mitochon…
3.karinkaz 04/25/2018
Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich's Ataxia and Other Severe Neurological Diseases
4.rjsllewellyn 02/28/2018
Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials
5.rjsllewellyn 02/13/2018
Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in PAH Patients From LARIAT Trial
6.karinkaz 03/30/2018
Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan
7.karinkaz 02/12/2018
long-term follow up
8.rjsllewellyn 03/22/2018
Announces positive top-line data from the Phase 2 LARIAT trial evaluating bardoxolone methyl for the treatme…
9.rjsllewellyn 07/10/2018
Reata Receives Orphan Drug Designation from the European Commission for Omaveloxolone for the Treatment of Friedreich's Ataxia
10.karinkaz 05/08/2018
Beats EPS estimates by $0.79
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW